{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=0&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1459977", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459977/answer", "answerText" : {"_value" : "<p>Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.<\/p><p>The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "158929"}
        , {"_value" : "159058"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:34:34.913Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, what progress has been made on the assessment of Evusheld for treating immunocompromised patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158928"}
    , {"_about" : "http://data.parliament.uk/resources/1459978", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459978/answer", "answerText" : {"_value" : "<p>Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.<\/p><p>The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "158928"}
        , {"_value" : "159058"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:34:34.947Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, when patients in the UK will have access to Evusheld as a preventative treatment for covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158929"}
    , {"_about" : "http://data.parliament.uk/resources/1459979", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459979/answer", "answerText" : {"_value" : "<p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T11:17:32.237Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what timeframe the UK Health Security Agency are working to in order to assess the effectiveness of Evusheld against the Omicron variant of covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158930"}
    , {"_about" : "http://data.parliament.uk/resources/1459980", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459980/answer", "answerText" : {"_value" : "<p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:55:40.647Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Immunosuppression: Coronavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of immunocompromised individuals who have (a) been hospitalised and (b) died as a result of covid-19 since the MHRA authorised Evusheld for use in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158931"}
    , {"_about" : "http://data.parliament.uk/resources/1459981", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459981/answer", "answerText" : {"_value" : "<p>The information requested is not held centrally as the shielding programme ended in September 2021. The Office for National Statistics\u2019 \u2018Coronavirus and clinically extremely vulnerable people in England\u2019 survey includes information on the behaviours of clinically extremely vulnerable people and their health and wellbeing, which is available at the following link:<\/p><p><a href=\"https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronavirusandclinicallyextremelyvulnerablepeopleinengland\" target=\"_blank\">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronavirusandclinicallyextremelyvulnerablepeopleinengland<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T10:42:26.587Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Immunosuppression: Coronavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many immunocompromised people remain shielding against covid-19; and what assessment he has made of the impact of that shielding on people's social interactions, mental health and economic activity.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158932"}
    , {"_about" : "http://data.parliament.uk/resources/1459983", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459983/answer", "answerText" : {"_value" : "<p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:56:19.283Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Immunosuppression: Coronavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he has assessed the number of immunocompromised patients who have received antiviral treatment in response to covid-19 and who have subsequently (a) been hospitalised and (b) died as a result of covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158933"}
    , {"_about" : "http://data.parliament.uk/resources/1459984", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459984/answer", "answerText" : {"_value" : "<p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"}
        }
        , "answeringMemberConstituency" : {"_value" : "Erewash"}
        , "answeringMemberPrinted" : {"_value" : "Maggie Throup"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T11:18:44.097Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Immunosuppression: Coronavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what proportion of immunocompromised patients received antiviral treatments within five days of the first symptoms, as recommended by the MHRA.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158934"}
    , {"_about" : "http://data.parliament.uk/resources/1459985", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459985/answer", "answerText" : {"_value" : "<p>The Department is committed to providing the best possible support for all claimants to meet their individual circumstances. Claimants with a health condition or disability, including those who are immunocompromised, continue to have tailored commitments agreed based on their personal circumstances, including considering the impact of their health and wider situation.<\/p><p>Any work-related requirements are set in discussion with the claimant, tailored to their individual capability and circumstances, making them realistic and achievable. The guidance available to DWP staff outlines the easements which may be applied including that work search reflects the type and location of jobs which are appropriate to the individual.<\/p><p>Although DWP does not routinely provide guidance specifically on supporting people who are immunocompromised, we do ensure that staff are aware of the sources of information available to them relating to medical conditions that are associated with this. Staff are signposted to tools, guidance support and websites to effectively use resources from both internal and external sites, such as information directly from the NHS.<\/p><p>This ensures that staff can access the most up to date advice and can use this to inform how they support individual customers.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4513", "label" : {"_value" : "Biography information for Mims Davies"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Sussex"}
        , "answeringMemberPrinted" : {"_value" : "Mims Davies"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T09:03:45.907Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Employment: Immunosuppression"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Work and Pensions, whether Work Coaches are being given guidance on immunocompromised patients; and whether that guidance includes avoiding recommendations for in-person work for those individuals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "158935"}
    , {"_about" : "http://data.parliament.uk/resources/1459869", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459869/answer", "answerText" : {"_value" : "<p>No specific assessment has been made.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
        }
        , "answeringMemberConstituency" : {"_value" : "Lewes"}
        , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T10:43:40.963Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cardiovascular Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of implementing a ten year plan to tackle cardiovascular disease, similar to the ten year plans for cancer and mental health in development.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "157563"}
    , {"_about" : "http://data.parliament.uk/resources/1459870", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459870/answer", "answerText" : {"_value" : "<p>The National Health Service will continue to ensure cardiovascular disease services remain a priority in the updated NHS Long Term Plan, including diagnostic and treatment services for patients with heart failure and heart valve disease. The NHS is investing in cardiac networks to support whole pathway improvements, from prevention, diagnosis, treatment through to end of life care.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
        }
        , "answeringMemberConstituency" : {"_value" : "Lewes"}
        , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
        , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-04-28T10:45:46.937Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-04-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cardiovascular Diseases"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has for cardiovascular disease, including heart valve disease, to remain a priority in the updated NHS Long Term Plan.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "157562"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=1&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z", "page" : 0, "startIndex" : 1, "totalResults" : 174, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}